PharmX TechnologiesASX:PHX 40 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates ASX:PHX with a GF Score™ of 40/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 606 Healthcare Providers & Services companies, PharmX Technologies ranks better than 91.25% on this metric.
The historical rank and industry rank for PharmX Technologies's Days Payable or its related term are showing as below:
ASX:PHX'
s Days Payable Range Over the Past 10 Years
Min: 87.33 Med: 165.88 Max: 398.86
Current: 398.86
During the past 13 years, PharmX Technologies's highest Days Payable was 398.86. The lowest was 87.33. And the median was 165.88.
ASX:PHX's Days Payable is ranked better than 91.25% of 606
companies
in the Healthcare Providers & Services industry
Industry Median: 58.205
vs ASX:PHX: 398.86
PharmX Technologies's Days Payable
declined
from Dec. 2024 (187.96) to Dec. 2025 (0.00).
It may suggest that PharmX Technologiesaccelerated paying its suppliers.
PharmX Technologies Days Payable Related Terms
PharmX Technologies Days Payable Historical Data
* Premium members only.
The historical data trend for PharmX Technologies's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PHX vs VEEV, BTSG, TEM: Days Payable Comparison
For the Health Information Services subindustry, PharmX Technologies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmX Technologies Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's Days Payable distribution charts can be found below:
* The bar in red indicates where PharmX Technologies's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
PharmX Technologies's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmX Technologies (ASX:PHX) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PharmX Technologies and its competitors. Over the past decade, PharmX Technologies' Days Payable has ranged from 87.33 to 398.86. According to the industry distribution chart, PharmX Technologies ranks #53 out of 606 companies in the Healthcare Providers & Services industry, placing it in the top 8.7%.
Is PharmX Technologies' Days Payable too high?
PharmX Technologies' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 87.33 to a high of 398.86. Based on the distribution chart, PharmX Technologies ranks #53 out of 606 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, PharmX Technologies has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' Days Payable compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, PharmX Technologies ranks #53 out of 606 companies for Days Payable. This places PharmX Technologies in the top 9% of its industry — outperforming the majority of peers. The industry median Days Payable is 58.21. Historically, PharmX Technologies' own Days Payable has ranged from 87.33 to 398.86 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.21, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PharmX Technologies and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmX Technologies's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.13 — trading 85.7% above its estimated fair value. The current Days Payable is 0.00. PharmX Technologies' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmX Technologies (ASX:PHX) Overvalued in 2026?
Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued.
The current stock price of A$0.13 is trading 85.7% above its estimated GF Value™ of A$0.07.
GuruFocus considers PharmX Technologies to be Significantly Overvalued.
Key valuation signals for ASX:PHX:
Days Payable: 0.00
GF Value™: A$0.07 vs. price of A$0.13 (85.7% above fair value)
No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
40GF Score
Get the complete analysis for ASX:PHX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PHX has been successfully added to your 
